secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001104659-22-117682
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx reports Q3 net loss of $3.5M; cash $10.6M; Phase 2b enrollment continues
------------------------------------------------------------------------------

- Net loss of $3.5M ($0.32 per diluted share) for Q3 2022, vs $4.6M ($0.46) in Q3 2021.
- Cash and cash equivalents $10.6M as of Sep 30, 2022, down from $13.0M at Dec 31, 2021.
- Phase 2b trial for C. difficile infection enrollment ongoing; added sites, expecting up to 30 total.
- Raised $4.225M in July 2022 via registered direct offering to institutional investor and executives.
- R&D expenses $1.6M in Q3 2022 vs $1.1M in Q3 2021, increase due to Phase 2b costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465922117682/0001104659-22-117682-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465922117682/tm2229909d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117682

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer